Janusita Tablet 50 mg (Sitagliptin Phosphate)
Sitagliptin Phosphate 62.04mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
MFDS item code 201503269 · Approved 2015.05.28
This product's status changed to Expired on 2025.05.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used to aid in blood sugar control for patients with type 2 diabetes. Initially, it can be administered alone in combination with dietary and exercise therapy. If sufficient blood sugar control is difficult with monotherapy, it can be used in conjunction with metformin. Additionally, it can be administered in combination with other antidiabetic medications such as sulfonylureas, metformin, thiazolidinediones, and insulin. When blood sugar control is challenging with multiple drug combination therapy, this medication can be added to improve blood sugar control. This medication enhances blood sugar management in patients with type 2 diabetes at various treatment stages.
For monotherapy or combination therapy, administer 100 mg once daily; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment As dosage adjustment according to renal function is necessary, assessment of renal function is recommended before and periodically after administration of this medicine. 1. No dosage adjustment is necessary in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is necessary in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.
This medication may cause severe hypersensitivity reactions, so if symptoms such as skin rash, angioedema, or difficulty breathing occur within 3 months after administration, usage should be immediately discontinued and medical attention sought. Acute pancreatitis may occur during the use of this drug; therefore, if symptoms such as abdominal pain, vomiting, or persistent abdominal discomfort appear, medical personnel should be informed immediately. This drug should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Patients with hypersensitivity to this drug or its components should not take it. Patients with decreased kidney function may need dosage adjustment; it is important to perform kidney function tests before administration. Hypoglycemia symptoms may occur while taking this drug, so blood sugar should be monitored regularly, especially when taken with insulin or sulfonylureas. Severe joint pain or blistering skin conditions may arise; consult a physician immediately if such symptoms occur. It is safer for pregnant or breastfeeding women not to take this drug. Elderly patients may have reduced kidney function, requiring dosage adjustments and kidney function testing. In case of overdose, immediate hospital visit for appropriate treatment is necessary; this drug can be partially removed by hemodialysis. Due to the potential for drug interactions, inform your doctor or pharmacist if you are currently taking any medications.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight closed container, kept at room temperature between 1 degree and 30 degrees Celsius. Proper storage will help maintain the effectiveness of the drug.
Bright beige, bilaterally convex, round film-coated tablet
30 tablets/box [10 tablets/PTPX3 units]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate 62.04mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.